NewLeftHeaderSNN

few clouds

63.9°F

Newport Beach

Volume 6, Issue 47  | June 11, 2021


Hoag offers clinical trial for pancreatic cancer patients

Hoag Memorial Hospital Presbyterian has been selected to conduct a Phase 2 clinical trial that researchers hope will demonstrate preliminary efficacy on pancreatic cancer.

Pancreatic cancer is one of the deadliest forms of cancer, with a five-year survival rate of just five percent. The new combination therapy uses the body’s own immune system to fight off deadly cancer cells.

“Hoag will be the first in Orange County to offer cell therapy for solid tumors, and was exclusively selected as the only hospital in Orange County to offer this pancreatic cancer trial as part of its new cell therapy program,” said Burton L. Eisenberg, M.D., F.A.C.S., executive director of Hoag Family Cancer Institute and the Grace E. Hoag Executive Medical Director Endowed Chair.

“Pancreatic cancer is a deadly cancer. Our present-day therapies are better than they use to be, but science is not anywhere near where it needs to be for these patients,” Dr. Eisenberg said. “Hoag continues to push forward and expand our ability to offer patients with advanced pancreatic cancer new hope as we deliver on innovative treatments, such as immunotherapy clinical trials.”

Hoag offers clinical trial

Click on photo for a larger image

Courtesy of Hoag Memorial Hospital Presbyterian

Hoag Cancer Center

This type of immunotherapy, also known as cell therapy, harnesses the body’s own immune system to target, kill and “remember” cancer cells. The agents involved in this pancreatic cancer clinical trial have been “designed” to find pancreatic cancer cells and initiate a large immune response against them. This may allow the body to develop its own antibodies to fight the cancer.

The treatment involves combining standard-of-care chemotherapy with investigational therapies, including cell therapy company NantKwest’s tumor-targeted natural killer cells, PD-L1 t-haNK; ImmunityBio’s superagonist, N-803, and the drug aldoxorubicin HCI. The trial will compare the results of the combination therapy against the use of chemotherapy alone in patients with locally advanced or metastatic pancreatic cancer.

“This unique approach to orchestrating the innate and adaptive immune systems to target and kill cancer cells may be an important new approach for pancreatic cancer patients,” said Patrick Soon-Shiong, M.D., chairman and chief executive officer of NantKwest and ImmunityBio. “We are excited to collaborate with Hoag to offer this investigational approach to more patients who suffer from pancreatic cancer.”

 Hoag’s commitment to innovation and excellence has earned the hospital a reputation as an effective partner for these investigational new therapies on par with leading academic centers.

“For many patients, especially those with advanced cancers, a clinical trial can offer a more effective treatment option than standard therapy,” Dr. Eisenberg said. “Hoag continues to relentlessly pursue innovative treatment options and leading-edge medical advances to deliver a level of care that is truly personalized medicine.”

For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it. or call 949.764.4577.

Who we are:

Tom Johnson, Publisher - [email protected]

Lana Johnson, Editor - [email protected]

Shaena Stabler, Co-Owner - [email protected]

Amy Senk, Duncan Forgey, Len Bose, Nancy Gardner and Sara Hall are our writers and/or columnists.

Michael Sterling is our Webmaster & Designer.

Email: [email protected] for questions about advertising

949.315.0259

Email: [email protected] with news releases, letters, etc.

949.212.1499

© 2021 Stu News Newport, LLC  |. All Rights Reserved